https://orcid.org/0000-0003-3965-5920
References
- González-Naranjo LA, Betancur OM, Alarcón GS, Ugarte-Gil MF, Jaramillo-Arroyave D, Wojdyla D, et al. Features associated with hematologic abnormalities and their impact in patients with systemic lupus erythematosus: data from a multiethnic Latin American cohort. Semin Arthritis Rheum 2016;45:675–83.
- Jiang N, Li M, Zhang M, Xu J, Jiang L, Gong L, et al. Chinese SLE Treatment and Research group (CSTAR) registry: clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus. PLoS One 2019;14:e0225516.
- Sammaritano LR. Antiphospholipid syndrome. Best Prac Res Clin Rheumatol 2020;34:101463.
- Atsumi T, Furukawa S, Amengual O, Koike T. Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. Lupus 2005;14:499–504.
- Barbhaiya M, Zuily S, Ahmadzadeh Y, Amigo MC, Avcin T, Bertolaccini ML, et al. Development of a new international antiphospholipid syndrome classification criteria phase I/II report: generation and reduction of candidate criteria. Arthritis Care Res (Hoboken) 2021;73:1490–501.
- George JN, el-Harake MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1994;331:1207–11.
- Ziakas PD, Giannouli S, Zintzaras E, Tzioufas AG, Voulgarelis M. Lupus thrombocytopenia: clinical implications and prognostic significance. Ann Rheum Dis 2005;64:1366–9.
- Bobba RS, Johnson SR, Davis AM. A review of the Sapporo and revised Sapporo criteria for the classification of antiphospholipid syndrome. Where do the revised Sapporo criteria add value? J Rheumatol 2007;34:1522–7.
- Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thrombo Haemost 2006;4:295–306.
- Riancho-Zarrabeitia L, Martínez-Taboada VM, Rúa-Figueroa I, Alonso F, Galindo-Izquierdo M, Ovalles J, et al. Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients? Clin Exp Rheumatol 2021;39:555–63.
- Chock YP, Moulinet T, Dufrost V, Erkan D, Wahl D, Zuily S. Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 2019;18:102395.
- Naranjo L, Ostos F, Gil-Etayo FJ, Hernández-Gallego J, Cabrera-Marante Ó, Pleguezuelo DE, et al. Presence of extra-criteria antiphospholipid antibodies is an independent risk factor for ischemic stroke. Fron Cardiovasc Med 2021;8:665741.
- Chatzidionysiou K, Samoli E, Sfikakis PP, Tektonidou MG. Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus. Ann Rheum Dis 2020;79:304–7.
- Sciascia S, Rubini E, Radin M, Cecchi I, Rossi D, Roccatello D. Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab. Ann Rheum Dis 2018;77:1694–5.
- De Marchi G, Quartuccio L, Bond M, De Vita S. Efficacy of belimumab for the long-term maintenance therapy of thrombocytopenia in systemic lupus erythematosus. Clin Exp Rheumatol 2017;35:1056.